Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy

[1]  M. Beckmann,et al.  Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy , 2015, Breast Cancer Research.

[2]  F Levi,et al.  European cancer mortality predictions for the year 2014. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  Matthias W. Beckmann,et al.  2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy , 2014, Nature Communications.

[4]  Robert Stevens,et al.  Gene Ontology Consortium , 2014 .

[5]  Y Magnusson,et al.  TGF-beta receptor type-2 expression in cancer-associated fibroblasts regulates breast cancer cell growth and survival and is a prognostic marker in pre-menopausal breast cancer , 2013, Oncogene.

[6]  Jing Luo,et al.  Combination with Methotrexate and Cyclophosphamide Attenuated Maturation of Dendritic Cells: Inducing Treg Skewing and Th17 Suppression In Vivo , 2013, Clinical & developmental immunology.

[7]  D. Altman,et al.  Prospective observational study of breast cancer treatment outcomes for UK women aged 18-40 years at diagnosis: the POSH study. , 2013, Journal of the National Cancer Institute.

[8]  I. Fentiman,et al.  Inflammation and breast cancer , 2013 .

[9]  Shimon Sakaguchi,et al.  The plasticity and stability of regulatory T cells , 2013, Nature Reviews Immunology.

[10]  Jaana M. Hartikainen,et al.  Large-scale genotyping identifies 41 new loci associated with breast cancer risk , 2013, Nature Genetics.

[11]  F. Couch,et al.  Identification of inherited genetic variations influencing prognosis in early-onset breast cancer. , 2013, Cancer research.

[12]  S. Ahn,et al.  Tumor-Associated Lymphocytes Predict Response to Neoadjuvant Chemotherapy in Breast Cancer Patients , 2013, Journal of breast cancer.

[13]  Stefan Michiels,et al.  Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  A. Kulić,et al.  Single Nucleotide Polymorphism in the Interleukin 12B Gene is Associated with Risk for Breast Cancer Development , 2012, Scandinavian journal of immunology.

[15]  Yusuke Nakamura,et al.  A genome-wide association study identifies locus at 10q22 associated with clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients in Japanese , 2022 .

[16]  F Levi,et al.  European cancer mortality predictions for the year 2012. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  D. Gabrilovich,et al.  Coordinated regulation of myeloid cells by tumours , 2012, Nature Reviews Immunology.

[18]  Wei Zheng,et al.  Novel genetic markers of breast cancer survival identified by a genome-wide association study. , 2012, Cancer research.

[19]  P. Watson,et al.  Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer , 2011, Breast Cancer Research.

[20]  D. Mougiakakos,et al.  Camouflage and sabotage: tumor escape from the immune system , 2011, Cancer Immunology, Immunotherapy.

[21]  C. la Vecchia,et al.  European cancer mortality predictions for the year 2011. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  R. Schreiber,et al.  Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion , 2011, Science.

[23]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[24]  M. Duechler,et al.  How do Tumors Actively Escape from Host Immunosurveillance? , 2010, Archivum Immunologiae et Therapiae Experimentalis.

[25]  D. Hafler,et al.  FOXP3+ regulatory T cells in the human immune system , 2010, Nature Reviews Immunology.

[26]  L. Coussens,et al.  Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity , 2010, Cancer and Metastasis Reviews.

[27]  Peter Kraft,et al.  A Genome-Wide Association Study of Prognosis in Breast Cancer , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[28]  Axel Benner,et al.  Effects of infiltrating lymphocytes and estrogen receptor on gene expression and prognosis in breast cancer , 2009, Breast Cancer Research and Treatment.

[29]  T. Gajewski,et al.  Costimulatory and coinhibitory receptors in anti‐tumor immunity , 2009, Immunological reviews.

[30]  O. Boyman,et al.  The role of chemokines in cancer immune surveillance by the adaptive immune system. , 2009, Seminars in cancer biology.

[31]  Srinivas Nagaraj,et al.  Myeloid-derived suppressor cells as regulators of the immune system , 2009, Nature Reviews Immunology.

[32]  P. Allavena,et al.  Macrophage polarization in tumour progression. , 2008, Seminars in cancer biology.

[33]  M. Tremelling,et al.  Genetics of inflammatory bowel disease: clues to pathogenesis. , 2008, British medical bulletin.

[34]  D. Vignali,et al.  How regulatory T cells work , 2008, Nature Reviews Immunology.

[35]  F. Ghiringhelli,et al.  Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity , 2008, Cancer Immunology, Immunotherapy.

[36]  S. Ostrand-Rosenberg,et al.  Immune surveillance: a balance between protumor and antitumor immunity. , 2008, Current opinion in genetics & development.

[37]  M. Mandalà,et al.  Transforming Growth Factor-β Signaling and Regulatory T Cells , 2007 .

[38]  Manuel A. R. Ferreira,et al.  PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.

[39]  L. Coussens,et al.  Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression , 2007, Breast Cancer Research.

[40]  D. Altman,et al.  PROSPECTIVE STUDY OF OUTCOMES IN SPORADIC VERSUS HEREDITARY BREAST CANCER , 2004 .

[41]  Stephen B Fox,et al.  Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  L. Zitvogel,et al.  Cancer despite immunosurveillance: immunoselection and immunosubversion , 2006, Nature Reviews Immunology.

[43]  Thomas J. Smith,et al.  Review: chemotherapy and hormonal therapy reduce recurrence and mortality at 15 years in early breast cancer , 2005, ACP journal club.

[44]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[45]  Weiping Zou,et al.  Immunosuppressive networks in the tumour environment and their therapeutic relevance , 2005, Nature Reviews Cancer.

[46]  J. Schlom,et al.  Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. , 2005, Blood.

[47]  K. Mills,et al.  Regulatory T cells: friend or foe in immunity to infection? , 2004, Nature Reviews Immunology.

[48]  B. Chauffert,et al.  CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative , 2004, European journal of immunology.

[49]  Toshihiro Tanaka.  The International HapMap Project , 2003, Nature.

[50]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[51]  R. Derynck,et al.  TGF-β signaling in cancer – a double-edged sword , 2001 .

[52]  P. Grambsch,et al.  Proportional hazards tests and diagnostics based on weighted residuals , 1994 .

[53]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[54]  Jacques Ferlay,et al.  GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012 , 2013 .

[55]  A. Liston,et al.  Regulatory T Cells , 2011, Methods in Molecular Biology.

[56]  Carsten Denkert,et al.  Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  M. Mandalà,et al.  Transforming growth factor-beta signaling and regulatory T cells. , 2007, Journal of Clinical Oncology.

[58]  Lisa M. Coussens,et al.  Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression , 2007 .

[59]  A. Balmain,et al.  TGF-beta signaling in tumor suppression and cancer progression. , 2001, Nature genetics.

[60]  R. Derynck,et al.  TGF-beta signaling in cancer--a double-edged sword. , 2001, Trends in cell biology.

[61]  Susumu Goto,et al.  KEGG: Kyoto Encyclopedia of Genes and Genomes , 2000, Nucleic Acids Res..